Rapcabtagene autoleucel Drug Asset Due Diligence Report 2026

This Rapcabtagene autoleucel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

149

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Rapcabtagene autoleucel can convert its Autologous CAR-T profile and CD19 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Rapcabtagene autoleucel (query alias: Rapcabtagene autoleucel)
Modality / target	Autologous CAR-T; CD19; CD19 modulators
Highest global status	Phase 2
Originator	Novartis AG
Active developers	Novartis Pharmaceuticals Corp., Novartis Pharmaceuticals Australia Pty Ltd., Novartis AG

The MCP disease footprint includes Scleroderma, Diffuse, Lupus Nephritis, Systemic Lupus Erythematosus. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07443137	Phase 1	Not yet recruiting	20	Primary endpoint not disclosed in English source
NCT07048197	Phase 1/2	Active, not recruiting	27	Primary endpoint not disclosed in English source
NCT06868290	Phase 2	Suspended	126	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

CLINICAL, CELLULAR KINETICS, PHARMACODYNAMICS AND BIOMARKER DATA UP TO 24 MONTHS AFTER RAPCABTAGENE AUTOLEUCEL (YTB323), A RAPIDLY MANUFACTURED CD19 CAR-T THERAPY, FROM AN OPEN-LABEL, PHASE 1/2 STUDY IN SEVERE REFRACTORY SLE

Phase 1/2; n=21; evaluation: Positive. Reported fields: Adverse Event: Cytokine release syndrome (CRS) = occurred in 12/21 (57%) patients; 10/12 received tocilizumab, and no patient required transfer to the intensive care unit

SAFETY AND EARLY EFFICACY OF RAPCABTAGENE AUTOLEUCEL (YTB323), AN AUTOLOGOUS CD19 DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN SEVERE REFRACTORY IDIOPATHIC INFLAMMATORY MYOPATHIES AND DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: PRELIMINARY ANALYSIS OF THE OPEN-LABEL AUTOGRAPH-IIM AND -SSC STUDIES

Phase 2; n=12; evaluation: Positive. Reported fields: AE = Transient (i.e., resolving ≤28 days post-infusion) Gr 3/4 neutropenia was reported in 5/12 patients (two IIM, three dcSSc). Additionally, one case of Gr 4 neutropenia adverse event (AE) with onset at Day (D) 18 post-infusion was reported in a dcSSc patient that resolved to Gr 3 by D33 post-infusion and returned to normal counts by D36. One mild hypogammaglobulinemia event was reported in one dcSSc patient, which did not require any treatment. ; AE = Transient (i.e., resolving ≤28 days post-infusion) Gr 3/4 neutropenia was reported in 5/12 patients (two IIM, three dcSSc). Additionally, one case of Gr 4 neutropenia adverse event (AE) with onset at Day (D) 18 post-infusion was reported in a dcSSc patient that resolved to Gr 3 by D33 post-infusion and returned to normal counts by D36. One mild hypogammaglobulinemia event was reported in one dcSSc patient, which did not require any treatment.

SAFETY, CELLULAR KINETICS AND EARLY EFFICACY OF RAPCABTAGENE AUTOLEUCEL (YTB323), A RAPIDLY MANUFACTURED AUTOLOGOUS CD19 CAR-T THERAPY, IN SEVERE, REFRACTORY AUTOIMMUNE DISEASES

Not disclosed; n=33; evaluation: Positive. Reported fields: AE = Only 1 SLE pt presented an immune cell-associated neurotoxicity syndrome (Gr 2), which resolved within 24 hrs with corticosteroids. AEs, including infections, were manageable and aligned with the safety profile of CAR-T cell therapies ; AE = Only 1 SLE pt presented an immune cell-associated neurotoxicity syndrome (Gr 2), which resolved within 24 hrs with corticosteroids. AEs, including infections, were manageable and aligned with the safety profile of CAR-T cell therapies

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Rapcabtagene autoleucel addresses Scleroderma, Diffuse, Lupus Nephritis, Systemic Lupus Erythematosus. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Autologous CAR-T—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 149 matched transaction record(s) under the scope “target-level comparable: CD19.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD19 records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-09-01	Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development	Preclinical	US$75.0M upfront; US$1,530.0M stated total
2026-08-28	CREATE Medicines Expands Clinical In Vivo CAR Pipeline and LNP Technology Suite by Forming Strategic Collaboration With WestGene	Preclinical	Financial terms not disclosed
2026-07-30	Curocell partners with Biruni to seek Türkiye approval for RIMQARTO in 2027	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Treatment of multiple sclerosis using a population of CD19 car-expressing cells”. The milestone feed surfaced a patent-application signal described as “Treatment of neuroimmune diseases using a population of CD19 car-expressing cells”. The milestone feed surfaced a patent-application signal described as “Decoy-resistant interleukin 18 armored cells and related methods”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Cytokine-release syndrome, neurotoxicity, infection, and treatment logistics
Durability of response and antigen escape
Manufacturing scalability, release testing, and site readiness

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO